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PPre-Operative Management
Timing of Pre-Operative Beta-Blocker
Treatment in Vascular Surgery Patients
Influence on Post-Operative Outcome
Willem-Jan Flu, MD,* Jan-Peter van Kuijk, MD,* Michel Chonchol, MD,† Tamara A. Winkel, MD,‡
Hence J. M. Verhagen, MD,‡ Jeroen J. Bax, MD,§ Don Poldermans, MD‡
Rotterdam and Leiden, the Netherlands; and Aurora, Colorado
Objectives This study evaluated timing of -blocker initiation before surgery and its relationship with: 1) pre-operative heart
rate and high-sensitivity C-reactive-protein (hs-CRP) levels; and 2) post-operative outcome.
Background Perioperative guidelines recommend -blocker initiation days to weeks before surgery, on the basis of expert
opinions.
Methods In 940 vascular surgery patients, pre-operative heart rate and hs-CRP levels were recorded, next to timing of
-blocker initiation before surgery (0 to 1, 1 to 4, 4 weeks). Pre- and post-operative troponin-T measure-
ments and electrocardiograms were performed routinely. End points were 30-day cardiac events (composite of
myocardial infarction and cardiac mortality) and long-term mortality. Multivariate regression analyses, adjusted
for cardiac risk factors, evaluated the relation between duration of -blocker treatment and outcome.
Results The -blockers were initiated 0 to 1, 1 to 4, and 4 weeks before surgery in 158 (17%), 393 (42%), and 389
(41%) patients, respectively. Median heart rate at baseline was 74 (17) beats/min, 70 (16) beats/min, and
66 (15) beats/min (p  0.001; comparing treatment initiation 1 with 1 week pre-operatively), and hs-CRP
was 4.9 (7.5) mg/l, 4.1 (.6.0) mg/l, and 4.5 (6.3) mg/l (p  0.782), respectively. Treatment initiated 1
to 4 or 4 weeks before surgery was associated with a lower incidence of 30-day cardiac events (odds ratio:
0.46, 95% confidence interval [CI]: 0.27 to 0.76, odds ratio: 0.48, 95% CI: 0.29 to 0.79) and long-term mortality
(hazard ratio: 0.52, 95% CI: 0.21 to 0.67, hazard ratio: 0.50, 95% CI: 0.25 to 0.71) compared with treatment
initiated 1 week pre-operatively.
Conclusions Our results indicate that -blocker treatment initiated 1 week before surgery is associated with lower pre-
operative heart rate and improved outcome, compared with treatment initiated 1 week pre-operatively. No
reduction of median hs-CRP levels was observed in patients receiving -blocker treatment 1 week compared
with patients in whom treatment was initiated between 0 and 1 week before surgery. (J Am Coll Cardiol 2010;
56:1922–9) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.05.056t
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eta-blockers are established therapeutic agents for patients
ith hypertension (1), heart failure (2), and coronary artery
isease (3). In the nonsurgical setting, -blockers are widely
sed for the prevention and treatment of coronary heart
isease and heart failure, both important determinants of
erioperative cardiovascular complications. Over the years
ultiple observational studies and randomized, controlled
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an Kuijk, and Winkel were supported by an unrestricted research grant from “Lijf en
even” Rotterdam, the Netherlands. All other authors have reported that they have
o relationships to disclose.(
Manuscript received March 16, 2010; revised manuscript received May 10, 2010,
ccepted May 11, 2010.rials have been performed to evaluate the effect of peri-
perative -blocker treatment in patients undergoing non-
ardiac surgery (4–15). The majority of these studies have
emonstrated cardioprotection derived from perioperative
-blocker treatment.
Proposed mechanisms by which -blockers exert intra-
perative cardioprotective effects include heart rate control,
eduction of systolic pressure and ventricular contractile
orce and its anti-arrhythmic properties. For the long-term,
-blockers reduce mechanical stress imposed on coronary
laques preventing plaque rupture (16). Patients receiving
-blockers tend to have lower plasma concentrations of
-reactive protein (CRP) than those not receiving
-blockers, and the anti-inflammatory properties of
-blockers are thought to stabilize coronary plaques
17–19). In addition, -blockers are known to lessen adverse
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unction, which is highly prevalent in the vascular surgery
opulation, by inhibiting the sympathetic nervous system and
ormone activation (A-type and B-type natriuretic peptides
nd norepinephrine) (20–22). Potential side effects associated
ith -blocker treatment are bradycardia, hypotension, and
troke. Factors that might relate to the effectiveness of
-blocker therapy and the occurrence of side effects are
ariations in treatment protocols, such as -blocker type,
-blocker dose, and timing of -blocker initiation before
urgery. However, the duration of -blocker treatment before
urgery and its effect on cardiovascular outcome has not been
valuated yet in a cohort of vascular surgery patients. The
resent study was conducted to evaluate timing of -blocker
nitiation and its influence on pre-operative heart rate, pre-
perative high-sensitivity CRP (hs-CRP) levels, and post-
perative outcome in vascular surgery patients.
ethods
tudy population. The original study population consisted
f 940 vascular surgery patients undergoing (open or endo-
ascular) lower extremity artery, carotid artery, or abdominal
orta repair, receiving pre-operative -blocker treatment.
pen abdominal aortic aneurysm repair and lower extremity
evascularization were considered procedures with high
ardiac risk. Carotid surgery and endovascular surgery were
onsidered procedures with intermediate-cardiac risk (23).
atients undergoing emergency surgery; randomized for
-blocker treatment in previous randomized, controlled
rials; and with pre-operative heart rate50 beats/min were
ot included in the present study. The study was performed
t the Erasmus Medical Center in Rotterdam, the Nether-
ands, during the period of 2002 to 2008. The study was
pproved by the hospital ethics committee and performed
ith informed consent of all patients.
aseline characteristics. Before surgery, a detailed history
as obtained from every patient. Clinical data included age,
ex, ischemic heart disease (defined as a history myocardial
nfarction [MI], coronary revascularization, or the presence
f pathologic Q waves on pre-operative electrocardiogram),
eart failure (defined as the presence of heart failure
ymptoms according the New York Heart Association
unctional classification or previous hospital admission for
ecompensated heart failure), and cerebrovascular disease
defined as a history of ischemic or hemorrhagic stroke). In
ddition, kidney dysfunction (serum creatinine 2.0 mg/
l), diabetes mellitus (fasting blood glucose 6.1 mmol/l or
equirement of antidiabetic medication), hypertension
blood pressure 140/90 mm Hg in nondiabetic patients
nd130/80 mm Hg in diabetic patients or requirement of
ntihypertensive medication), hypercholesterolemia (low-
ensity lipoprotein cholesterol 3.5 mmol/l or requirement
f lipid-lowering medication), chronic obstructive pulmo-
ary disease (according to the Global Initiative on Obstruc-
ive Lung Diseases classification), and smoking status were re- dorded as well. Peripheral blood
amples for hs-CRP in mg/l, mea-
ured by a nephelometric assay on
Beckman-Immage analyzer
Beckman-Coulter, Fullerton,
alifornia), were routinely per-
ormed 1 day before surgery.
edication use. The use of the
rescription medications was
aptured at baseline and included
-blockers, statins, aspirin, clopidogrel (at the Erasmus
edical Center antiplatelet therapy is continued during
urgery per protocol), oral anticoagulants, inhibitors of the
enin-angiotensin-aldosterone system (RAAS) (angiotensin-
onverting enzyme inhibitors, angiotensin-II receptor
lockers, renin inhibitors, aldosterone antagonists), and
iuretics. During the first pre-operative visit at the outpa-
ient clinic, pre-operative -blocker use was established in
atients already receiving -blockers; and in patients not
lready receiving -blockers, pre-operative -blocker treat-
ent was initiated. Pre-operative -blocker use was subdi-
ided according to initiation time of treatment: 0 to 1, 1
o 4 or4 weeks before surgery. All patients returned to the
utpatient clinic after 1 week; and -blocker dosage, if
eeded, was adjusted and titrated as tolerated to obtain a
re-operative heart rate between 60 and 70 beats/min (24).
his protocol could not be followed in patients in which
-blocker treatment was initiated 1 week before surgery.
tudy outcomes. Main study end points were 30-day
ardiovascular events and long-term mortality. The 30-day
ardiovascular events were the composite of myocardial
amage (defined as myocardial ischemia or infarction),
troke, and mortality up to 30 days after surgery. Serial
lectrocardiograms and troponin-T measurements were ob-
ained from all patients before surgery; post-operatively on
ays 1, 3, and 7; and before discharge. Perioperative
yocardial ischemia was defined for patients with normal
re-operative and elevated (0.03 ng/ml) post-operative
roponin-T levels. Elevated troponin-T levels in combina-
ion with electrocardiographic changes (new onset ST-T
hanges and pathological Q waves) or with or without
ymptoms of angina pectoris defined MI (25). Patients with
levated troponin-T levels before surgery were not included
n the study. Long-term mortality was assessed by ap-
roaching the municipal civil registries. Mean follow-up
as 2.2  1.8 years. Secondary end points were pre-
perative heart rate (beats/min) and hs-CRP levels (mg/l).
eripheral blood samples for hs-CRP were routinely per-
ormed 1 day before surgery. Optimal specificity and sensi-
ivity of hs-CRP to predict post-operative outcome was
alculated with receiver-operating characteristic curve anal-
ses, and a cutoff value 6.5 mg/l was used in the analyses.
tatistical analysis. Dichotomous data are described as
umbers and percentages, and categorical data are compared
ith the chi-square test. The continuous variable age is
Abbreviations
and Acronyms
CI  confidence interval
hs-CRP  high-sensitivity
C-reactive protein
MI  myocardial infarction
RAAS  renin-angiotensin-
aldosterone systemescribed as mean  SD and compared with analysis of
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re described as median interquartile range and compared
ith the Mann–Whitney U test. The relation between
-blocker use and perioperative myocardial damage was
valuated with logistic regression analyses. In addition, the
elation between -blocker use and long-term follow-up
as evaluated with Cox regression analysis. Multivariate
nalyses were adjusted for demographic data (age and sex),
ardiovascular risk factors (ischemic heart disease, cerebro-
ascular disease, heart failure, kidney dysfunction, diabetes
ellitus, hypertension, hypercholesterolemia, chronic ob-
tructive pulmonary disease, and smoking status), type of
urgery, and medication use (statins, aspirin, and RAAS
nhibitors). We report crude and adjusted odds and hazard
atios with their 95% confidence intervals (CIs). For all
ests, a p value 0.05 (2-sided) was considered significant.
Baseline CharacteristicsTable 1 Baseline Characteristics
Baseline Characteristics
0
(n
Demographic data
Age, yrs (SD)
Median HR at day of surgery, beats/min (IQR)
Male 1
Medical history
Ischemic heart disease
Heart failure
Cerebrovascular disease
Renal dysfunction
Diabetes mellitus
Hypertension 1
Hypercholesterolemia
Smoker, current
Chronic obstructive pulmonary disease
Surgery
Open
Lower extremity revascularization
Abdominal aorta repair
Carotid artery repair
Endovascular
Lower extremity revascularization
Abdominal aorta repair
Carotid artery repair
Echocardiography
Left ventricular ejection fraction 40%
Laboratory (IQR)
Median hs-CRP (mg/l) 1 day before surgery
Medication
Statins 1
Aspirin
Clopidogrel
Oral anticoagulants
RAAS inhibitors
Diuretics
Values are percentages, unless otherwise indicated. *p value: compar
1 week.
HR  hazard ratio; hs-CRP  high-sensitivity C-reactive protein; IQR  intell analyses were performed with SPSS version 15.0 statis-
ical software (SPSS, Inc., Chicago, Illinois).
esults
aseline characteristics. The baseline study population
onsisted of 940 patients undergoing carotid artery stenosis
n 215), abdominal aortic aneurysm (n 405), and lower
xtremity artery (n  153) repair and receiving pre-
perative -blocker treatment. A total of 661 (70%) patients
eceived bisoprolol, 186 (20%) received metoprolol succi-
ate, 49 (5%) received atenolol, and 44 (5%) patients
eceived other -blockers. Clinical parameters stratified by
iming between -blocker initiation and vascular surgery are
emonstrated in Table 1. The majority of patients were men
77%), and the mean (SD) age was 67 (10) years. Patients
of -Blocker Initiation Before Surgery
p Value*
ek
8)
>1–4 Weeks
(n  393)
>4 Weeks
(n  389)
1) 67 (10) 67 (10) 0.920
7) 70 (16) 66 (15) 0.001
4) 310 (79) 279 (76) 0.437
5) 142 (36) 208 (54) 0.01
) 35 (9) 50 (13) 0.090
4) 118 (30) 137 (35) 0.009
8) 55 (14) 87 (22) 0.010
0) 100 (26) 126 (33) 0.100
4) 236 (60) 290 (75) 0.01
0) 165 (42) 198 (51) 0.032
8) 167 (43) 157 (40) 0.313
7) 136 (35) 134 (34) 0.154
8) 260 (66) 247 (63) 0.170
8) 92 (23) 110 (28) 0.153
8) 110 (28) 95 (24) 0.163
2) 58 (15) 42 (11) 0.973
2) 133 (34) 142 (37) 0.170
0) 30 (8) 43 (11) 0.244
) 83 (21) 61 (16) 0.091
) 20 (5) 38 (10) 0.107
) 71 (18) 84 (22) 0.312
5) 4.1 (6.0) 4.5 (6.3) 0.782
) 289 (74) 296 (76) 0.271
) 228 (58) 239 (61) 0.187
21 (5) 30 (8) 0.371
) 57 (15) 71 (18) 0.360
) 138 (35) 197 (51) 0.01
) 85 (22) 116 (30) 0.030
groups 1 to 4 weeks and 4 weeks taken together with group 0 toTiming
–1 We
 15
68 (1
74 (1
17 (7
56 (3
12 (8
69 (4
28 (1
48 (3
01 (6
79 (5
75 (5
42 (2
91 (5
29 (1
29 (1
33 (2
67 (4
16 (1
27 (17
24 (15
26 (17
4.9 (7.
18 (75
95 (60
9 (6)
25 (16
57 (36
40 (25
ison ofrquartile range; RAAS  renin-angiotensin-aldosterone system.
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November 30, 2010:1922–9 Beta-Blocker Treatment and Vascular Surgeryeceiving -blocker treatment1 week before surgery more
ften had a history of ischemic heart disease, kidney
ysfunction, and hypertension and more often received
AAS inhibitors and diuretics, compared with patients
eceiving -blocker treatment 1 week before surgery.
re-operative heart rate, pre-operative hs-CRP, and
ost-operative outcome. As demonstrated in Table 1,
atients receiving -blocker treatment 1 week before
urgery had lower median resting heart rate at day of
urgery, compared with patients receiving -blocker treat-
ent 1 week pre-operatively (p  0.001). No significant
ifference was observed in median pre-operative hs-CRP
evels between these groups (p  0.782). In statin-naive
atients (n  237), no significant difference in median
re-operative hs-CRP levels was observed between these
roups as well (p  0.786). However, a subanalysis
emonstrated that median hs-CRP concentrations were
ignificantly lower in patients receiving statin treatment 1
eek before surgery (median hs-CRP  4.0 mg/l), com-
ared with statin-naive patients (median hs-CRP  5.7
g/l; p  0.043).
The influence of median pre-operative heart rate and
s-CRP toward post-operative outcome is demonstrated in
igure 1. An hs-CRP concentration 6.5 mg/l (26 of 139
19%) or an increased heart rate70 beats/min (45 of 243
19%) were both associated with an increased incidence of
erioperative events (Fig. 1), compared with patients with
ormal heart rate (60 to 70 beats/min) in combination with
n hs-CRP concentration 6.5 mg/l (61 of 438  14%).
atients with high heart rate (70 beats/min) in combina-
ion with an hs-CRP 6.5 mg/l had the highest incidence
f perioperative events (30 of 120  25%) with an overall
value 0.001. In addition, an hs-CRP concentration
6.5 mg/l (22 of 139  16%) or an increased heart rate
70 beats/min (41 of 243  17%) were both associated
ith an increased incidence of long-term mortality (Fig. 1),
ompared with patients with normal heart rate (60 to 70
Figure 1 Influence of Pre-Operative Heart Rate and hs-CRP Tow
hs-CRP  high-sensitivity C-reactive protein.eats/min) in combination with an hs-CRP concentration
V
g6.5 mg/l (52 of 438  12%). Patients with high heart rate
70 beats/min) in combination with an hs-CRP 6.5
g/l had the highest incidence of long-term mortality (27
f 120  23%) with an overall p value 0.001.
nitiation of -blocker treatment and post-operative
utcome. During the first 30 days after surgery 150 (16%)
atients had troponin-T release, of which 114 (76%) had
yocardial ischemia and 36 (24%) had MI. The study end
oint of 30-day cardiovascular events (composite of myo-
ardial damage, stroke, and 30-day mortality) was reached
y 162 patients, as demonstrated in Table 2. In total, 27%
42 of 158) of patients receiving -blocker treatment 1
eek before surgery had a perioperative 30-day cardiovas-
ular event, compared with 15% (120 of 782) of patients
ho received pre-operative -blocker treatment 1 week
efore surgery (Table 3). Multivariate analyses demon-
trated that -blocker treatment initiated 4 and 1 to 4
eeks before surgery were both associated with a reduced
ncidence of 30-day cardiovascular events with odds ratios of
.46 (95% CI: 0.27 to 0.48) and 0.48 (95% CI: 0.29 to 0.79)
ompared with patients in whom -blocker treatment was
nitiated 1 week pre-operatively (Table 3). Subanalyses
ost-Operative Outcome
iming of -Blocker Initiation Before Surgerynd Post-Operative OutcomeTable 2 Timing of -Block r Initiation Before Surgeryand Post-Operative Outcome
Post-Operative
Outcome
Timing of -Blocker Initation
Before Surgery
p Value*
0–1 Week
(n  158)
>1–4 Weeks
(n  393)
>4 Weeks
(n  389)
30-day outcome
Troponin-T release 40 (25) 54 (14) 56 (14) 0.032
Mortality 6 (4) 8 (2) 11 (3) 0.495
Stroke 3 (19) 2 (0.5) 2 (0.5) 0.021
Cardiovascular events 42 (27) 58 (15) 62 (16) 0.001
Long-term outcome
Mortality 30 (19) 55 (14) 57 (15) 0.039ard Palues are n (%). *p value: comparison of groups1 to 4 weeks and4 weeks taken together with
roup 0 to 1 week.
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Beta-Blocker Treatment and Vascular Surgery November 30, 2010:1922–9erformed in patients undergoing surgery associated with
igh and intermediate cardiac risk are demonstrated in
able 3.
During long-term follow-up 142 (15%) patients died.
umulative post-operative survival stratified to -blocker
reatment initiation time is demonstrated in Figure 2
log-rank p  0.01). Of the patients who died, 33% (47 of
42) had perioperative myocardial damage. In total, 19%
30 of 158) of patients receiving -blocker treatment 1
eek before surgery died, compared with 15% (112 of 782)
f patients who received pre-operative -blocker treatment
1 week before surgery (Table 4). Of the patients who died,
2 patients (51%) had myocardial damage during 30-day
ollow-up. Multivariate analyses demonstrated that -blocker
reatment initiated 4 and 1 to 4 weeks before surgery was
ssociated with a reduced incidence of long-term mortality
Association of Time, Between Timing of -Blockof 30-Day Cardiovascular Events in Vascular SurTable 3 Association of Time, Between Timinof 30-Day Cardiovascular Events in
30-Day Cardiovascular Events n (%)
All 162/940
Timing of -blocker initiation
0–1 week pre-operatively 42/158 (27)
1–4 weeks pre-operatively 58/393 (15)
4 weeks pre-operatively 62/389 (16)
High-risk procedures 125/469
Timing of -blocker initiation
0–1 week pre-operatively 25/58 (43)
1–4 weeks pre-operatively 44/204 (22)
4 weeks pre-operatively 56/207 (27)
Intermediate-risk procedures 37/471
Timing of -blocker initiation
0–1 week pre-operatively 17/100 (17)
1–4 weeks pre-operatively 14/189 (7)
4 weeks pre-operatively 6/182 (3)
Multivariate analyses reported in this table are adjusted for age, s
dysfunction, diabetes mellitus, hypertension, hypercholesterolemia, ch
CI  confidence interval.
Figure 2 Cumulative Long-Term Survival
Stratified to Timing of -Blocker Initiation
Log-rank p value: comparison of groups 1 to 4 weeks
and 4 weeks with group 0 to 1 week.tith hazard ratios of 0.52 (95% CI: 0.21 to 0.67) and 0.50
95% CI: 0.25 to 0.71) compared with patients in whom
-blocker treatment was initiated 1 week pre-operatively
Table 4). Subanalyses performed in patients undergoing
urgery associated with high and intermediate cardiac risk are
emonstrated in Table 4.
iscussion
he present study evaluated the influence of timing between
-blocker treatment initiation and vascular surgery out-
ome. Our results indicate that -blocker treatment initi-
ted 1 week before surgery is associated with a reduction
f pre-operative heart rate compared with treatment initi-
ted 1 week before surgery. Of note, no reduction of
s-CRP levels was observed. Importantly, our results indi-
ate that -blocker treatment initiated 1 week before
urgery is associated with improved post-operative outcome
ompared with treatment initiated 1 week before surgery,
hich could be related to adequate heart rate control.
Surgical procedures are associated with tachycardia and
ncreased myocardial contractility leading to an increased
xygen demand (26). Maintaining a balance between the
yocardial oxygen demand and supply is key to prevent
erioperative cardiac events.
Randomized, controlled trials demonstrated that -blockers
educe the incidence of adverse cardiac events in patients
ndergoing intermediate-risk noncardiovascular surgery and
n patients undergoing high-risk vascular surgery (10,27).
roposed mechanisms by which -blockers exert intraop-
rative cardioprotective effects are: 1) heart rate control with
ubsequent prolongation of coronary diastolic filling time;
nd 2) antiarrhythmic properties reducing the risk for
itiation and PresenceP ie ts-Bl cker Initiation and Presence
ular Surgery Patients
Univariate Multivariate
ds Ratio 95% CI Odds Ratio 95% CI
1.00 1.00
0.48 0.30–0.78 0.46 0.27–0.76
0.54 0.40–0.88 0.48 0.29–0.79
1.00 1.00
0.35 0.18–0.66 0.38 0.19–0.79
0.66 0.36–0.97 0.58 0.29–0.91
1.00 1.00
0.49 0.23–0.97 0.51 0.13–0.79
0.10 0.03–0.34 0.12 0.02–0.25
emic heart disease, cerebrovascular disease, heart failure, kidney
bstructive pulmonary disease, smoking status, and medication use.er Ingeryof
Vasc
Od
ex, ischachycardia (17). In addition, -blockers are known to
r
(
i
(

R
h
L
c
l
a
a
e
a
b
t
m
h
d
t
v
m
m
o
b
s
t
p

o
r
l
a
r
p
e
s
t
p
p
o
a
p
v
t
m
w
A
p
b
m
w
p
i
w

D
E
e
o
s
t
e
ronic o
1927JACC Vol. 56, No. 23, 2010 Flu et al.
November 30, 2010:1922–9 Beta-Blocker Treatment and Vascular Surgeryeduce systolic pressure and ventricular contractile force
17,19).
In the long-term, -blockers reduce mechanical stress
mposed on coronary plaques preventing plaque rupture
16). In addition, the anti-inflammatory properties of
-blockers are thought to stabilize coronary plaques (17,19).
ecently, it is suggested that left ventricular dysfunction is
ighly present in the vascular surgery population (20).
ong-term -blocker therapy is known to reduce adverse
ardiac remodelling in patients with impaired left ventricu-
ar function by inhibiting the sympathetic nervous system
nd hormone activation (A- and B-type natriuretic peptides
nd norepinephrine) (21,22).
Over the years, multiple randomized, controlled trials
valuated the effectiveness of perioperative -blocker use
nd provided conflicting evidence with regard to its
enefit (4–15). In 1996, Mangano et al. (9) hypothesized
hat strict perioperative heart rate control with atenolol
ight limit the development of perioperative ischemia in
igh-risk surgery patients. In addition, Raby et al. (11)
emonstrated a beneficial effect of heart rate control with
he short-acting -blocker esmolol, immediately after
ascular surgery. In the present study, -blocker treat-
ent 1 week before surgery was associated with lower
ean pre-operative heart rate and improved post-operative
utcome.
In 2002, Jenkins et al. (18) evaluated the association
etween -blockers and plasma CRP levels in patients with
ymptomatic coronary artery disease. The authors found
hat patients who were treated with -blockers had lower
lasma concentrations of CRP than those not receiving
-blockers; however, no differences among types or dosages
f -blockers were evident. In our study, all patients
Association of Time, Between Timing of -Blockand Long-Term Mortality of Vascular Surgery PaTable 4 Association f Time, Between Timinand Long-Term Mortality of Vascula
Long-Term Mortality n (
All 142/940
Timing of -blocker initiation
0–1 week pre-operatively 30/158 (1
1–4 weeks pre-operatively 55/393 (1
4 weeks pre-operatively 57/389 (1
High-risk procedures 93/469
Timing of -blocker initiation
0–1 week pre-operatively 17/58 (2
1–4 weeks pre-operatively 38/204 (1
4 weeks pre-operatively 43/207 (2
Intermediate-risk procedures 49/471
Timing of -blocker initiation
0–1 week pre-operatively 13/100 (1
1–4 weeks pre-operatively 17/189 (9
4 weeks pre-operatively 13/182 (7
Multivariate analyses reported in this table are adjusted for age, s
dysfunction, diabetes mellitus, hypertension, hypercholesterolemia, ch
CI  confidence interval; HR  hazard ratio.eceived -blocker treatment, and our results indicate that songer duration of -blocker therapy is not associated with
n additional reduction of hs-CRP levels. No additional
eduction of hs-CRP levels was observed in statin-naive
atients receiving treatment 1 week before surgery. How-
ver, patients receiving statin treatment 1 week before
urgery did have mean lower hs-CRP levels before surgery
han those not receiving statin treatment, in line with
revious studies (28–30). The NAPLES (Novel Ap-
roaches for Preventing or Limiting Events)-II trial dem-
nstrated that even a single high (80 mg) loading-dose of
torvastatin reduced the incidence of periprocedural MI in
atients undergoing elective percutaneous coronary inter-
ention (29).
In 2008, the POISE (Perioperative Ischemic Evaluation)
rial randomized patients to receive either high-dosage
etoprolol succinate on the day of surgery or placebo
ithout titration of the dose according to heart rate (5).
lthough a 30% decrease in nonfatal MI was found in
atients treated with high-dose metoprolol succinate, this
eneficial effect was accompanied by a 33% increase in total
ortality and a 2-fold increased risk in stroke, compared
ith placebo. Metoprolol is metabolized via the CYP 2D6
athway and might interact with other drugs, administered
ntra-operatively and metabolized via the CYP 2D6 path-
ay as well, underlining the importance for adequate
-blocker dosage (31). Poldermans et al. (10) performed the
ECREASE (Dutch Echocardiographic Cardiac Risk
valuation Applying Stress Echocardiography)-I trial and
valuated the effect of low-dose bisoprolol on post-operative
utcome after vascular surgery. Bisoprolol treatment was
tarted an average of 37 days before surgery with careful
itration according to heart rate to prevent adverse side
ffects. In contrast to the POISE trial, the incidence of
itiation-Bl cker Initiation
gery Patients
Univariate Multivariate
HR 95% CI HR 95% CI
1.00 1.00
0.57 0.32–0.91 0.52 0.21–0.67
0.62 0.35–0.94 0.50 0.25–0.71
1.00 1.00
0.31 0.17–0.57 0.37 0.20–0.69
0.47 0.27–0.83 0.46 0.26–0.83
1.00 1.00
0.59 0.27–0.91 0.46 0.21–0.94
0.37 0.16–0.88 0.37 0.15–0.91
emic heart disease, cerebrovascular disease, heart failure, kidney
bstructive pulmonary disease, smoking status, and medication use.er Intientsg of
r Sur
%)
9)
4)
5)
9)
9)
0)
3)
)
)
ex, ischtroke in the DECREASE-I trial was comparable with
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onfatal MI from 34% in the standard-care group to 3.4%
n the bisoprolol-treated group. Interestingly, in all clinical
rials that did not demonstrate a difference in post-operative
utcome between -blocker– and placebo-treated groups,
-blocker treatment was initiated 1 week before surgery
4,7,14,15). This could provide an explanation for the
onflicting results with regard to the effect of perioperative
-blocker treatment in the published data up to now. In the
urrent study, the stroke rate in patients in whom -blocker
reatment was initiated 0 to 1 week pre-operatively (n  158)
as increased, compared with patients receiving -blocker
reatment 1 week before surgery. In this group, 3 patients
r 1.9% suffered a stroke, which is higher compared with the
OISE trial; however, this difference is based on very small
umbers. In addition, of the patients who received
-blocker treatment 1 week before surgery (n  782),
nly 4 patients had a stroke, which is less compared with the
roup of patients receiving metroprolol succinate in the
OISE trial and comparable with the placebo group de-
cribed in the POISE trial. This result underlines the
mportance of -blocker titration 1 week before surgery.
The most recent European Society of Cardiology guide-
ines, addressing perioperative care, recommend that
-blocker treatment should be initiated between 30 days
nd at least 1 week before surgery (24). This recommenda-
ion is based on an expert opinion with a level of evidence C.
n addition, in the 2009 “American College of Cardiology
oundation/American Heart Association Focused Update
n Perioperative -Blockade for Noncardiac Surgery,” it is
uggested that, when possible and where indicated,
-blockers should be started days to weeks before elective
urgery (32). The results from the present study under-
ine the importance of -blocker initiation 1 week before
ascular surgery. One of the reasons we did not observe
etter survival of patients in whom -blocker treatment was
nitiated 4 weeks, compared with patients in whom
-blocker treatment was initiated 4 weeks before surgery,
s an increased prevalence of ischemic heart disease and
enal dysfunction present in this patient group.
With regard to perioperative -blocker treatment, the
ollowing questions could be asked. First, could one give just
slightly higher -blocker dose to achieve adequate heart
ate control and routinely start the treatment 1 week
efore surgery to reach an improved post-operative outcome
s well? As we have learned from the POISE trial, treatment
ith high -blocker dosage and without up-titration is
ccompanied with an increased incidence of side effects
bradycardia, hypotension, and stroke). In the present study,
he incidence of stroke was increased in patients receiving
-blocker treatment1 week before surgery compared with
atients receiving -blocker treatment 1 week before
urgery. In patients in whom -blocker therapy is initiated
hortly before surgery, there might be an increased risk of
ide effects, because treatment is initiated too aggressively bnd the response to -blocker therapy cannot be adequately
onitored during this short period of time, leading to an
verdosing danger (33). In addition, as recently described by
eattie et al. (34), -blocked patients do not seem to
olerate surgical anemia when compared with patients who
re naive to -blockers. Although one could assume that
igh -blocker dosage might prevent compensatory mech-
nisms evoked by perioperative anemia, such as an increase
n heart rate, optimal -blocker titration in anemic patients
emains to be elucidated. A second question to be asked is
hat to do with -blocker–naive patients in urgent need
or vascular surgery (i.e., should surgery be postponed to
btain first adequate heart rate control). The results of
his study have demonstrated that -blocker initiation
1 week before surgery is not associated with a reduction
f hs-CRP concentrations, which might indicate that
nti-inflammatory effects are achieved within days. In
ddition, -blocker initiation at day of surgery is known to
educe pre-operative heart rate as well (9). Treatment with
he ultra-short-acting -blocker esmolol can be performed
afely during the perioperative period, as demonstrated by
aby et al. (11). The short-acting character of esmolol could
imit the occurrence of adverse myocardial events in patients
ndergoing urgent vascular surgery; however, future studies
re needed to address this point.
tudy limitations. Potential limitations of these data merit
onsideration. First, the study population consisted of pa-
ients referred to a tertiary referral center and might not fully
epresent a general population scheduled for elective vascu-
ar surgery. Second, although more than 900 patients were
ncluded in the study, the observational and retrospective
ature of the study remains a limitation. Third, nonfatal
ardiovascular events during long-term follow-up were not
ddressed; however, the study focused on the hard end point
f long-term mortality. Fourth, data in the current study are
ot randomized according to initiation time of -blocker
reatment. Although multivariate analyses were adjusted for
nown confounders, the possibility of uncaptured con-
ounders persists.
onclusions
he present study provides an indication that -blocker
herapy initiated 1 week before surgery is associated with
educed pre-operative heart rate and improved post-
perative outcome, compared with patients in whom
-blocker therapy was initiated 1 week before vascular
urgery. In addition, no reduction of median hs-CRP levels
as observed in patients receiving -blocker treatment 1
eek compared with patients in whom treatment was
nitiated between 0 and 1 week before surgery. Therefore,
mproved post-operative outcome of patients receiving
-blocker treatment 1 week before vascular surgery could
e related to adequate heart rate control.
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